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METHODS Between October 2013 and July 2014, 90 patients who are undergoing TAVI were prospectively included in the OCEAN-TAVI registry from 3 Japanese centers (Keio university hospital, Toyohashi heart center, and Teikyo university hospital). Between March 20 09 and December 201 2, 181 consecutive patients undergoing TAVI who had pre-procedural MDCT at Institut Cardiovasculaire Paris Sud were prospectively included in the European cohort. We compared MDCT aortic annulus measurement of these 2 cohorts. BACKGROUND MitraClip has been increasingly performed in Asian countries since 2011. Our study is to evaluate the effectiveness of improvement of heart failure symptoms and functional status in heart failure patients with percutaneous method of reduction of mitral incompetence (MI) with the MitraClip system. METHODS Patients were selected for the MitraClip procedure based on the consensus of the Heart Team in our center. Between February 2012 and December 2013, 24 patients considered high risk as surgical candidates undergone percutaneous therapy for severe MI using the MitraClip. All the patients underwent clinical and echocardiographic evaluation at baseline, and at 6-month follow-up. Mortality data, including cause of death, were collected.
RESULTS

The mean age was 67 years (53-86), 58.3% (n ¼ 14) was male with a mean logistic EuroSCORE of 21%. At baseline, 90% of patients were in New York Heart Association (NYHA) functional class III or IV and 46% of patients had a left ventricular ejection fraction (LVEF) 50%. 45.8% (n¼11) patients presented with functional mitral regurgitation (FMR) and 54.2% (n¼13) patients presented with degenerative mitral regurgitation (DMR). Procedural success was achieved in 96% of patients. Severity of MR was reduced in all successfully treated patients, 18 (75%) were discharged with MR 2þ. There was improvement in the severity of MI at 6 months, compared with baseline (p < 0.0001), Thirty-day mortality was 6%. At 6 months, approximately 90% of patients had New York Heart Association functional class II or class I (p <0.0001).
CONCLUSION
Results of the study demonstrate that mitral incompetence reduction with MitraClip treatment is effective, low risk, and leads to significant improvement in NYHA functional class in approximately 90% of patients with heart failure. BACKGROUND A novel and innovative transfemoral aortic valve implantation (TF-AVI) system was used to treat 89 patients with severe aortic stenosis in a CE mark trial. This single-arm registry was performed at 6 clinical sites in Brazil, Germany and Japan. The first patient was implanted in January 2012 and the last study implant procedure took place in early October 2013.
METHODS These 89 high-risk patients afflicted with severe aortic stenosis were treated in single-arm trials conducted at 6 centers in Brazil, Germany and Japan. Treated patients have a mean age of 83.7 AE 4.4 years, an STS Score of 7.5 AE 8.2%, and a logistic EuroSCORE of 26.6AE 7.7%. Baseline mean aortic gradient was 43.6 AE 17.1 mmHg and mean AVA was 0.7 AE 0.2 cm 2 . Nearly all patients presented in NYHA ClassIII/IV at screening (n¼84) and 65.2% were female. All patients provided EC-approved written informed consent.
RESULTS Procedure success rate was 94.4% (n¼84) with 3 valve-invalve procedures and 2 failed implantations due to one instance of annular rupture and one case of bioprosthesis leaflet tear. Both failed procedures occurred during post-dilatation. The implant procedures were performed using small, medium and large valves covering an annular range of 21 mm to 27 mm. At 30 days there were 3 deaths, 2 strokes and no MI reported. Only 8 new pacemaker implantations were required for a rate of 9.0%. Freedom from VARC II combined safety at 30 days was 84.3% (n¼75). Echocardiography at 30 days revealed only 4 patients (4.9%) with moderate (grade 2) paravalvular leak -there were no patients with a paravalvular leak above grade 2. The mean gradient was reduced to 8.0 AE 2.9 mmHg and the aortic valve area was 1.8AE 0.3 cm 2 . At 12 months, all-cause mortality was 22.5% (n¼20) with 3 additional strokes and one myocardial infarction reported.
CONCLUSION Outcomes from treatment with this new 2 nd Generation TF-AVI system confirm its feasibility of use and safety out to one year. In September 2014 this device received CE mark approval, and further postmarket data may be expected in the near future. 
